Search
Menu
Home
HTB
2004
April
03
HTB
3 April 2004
Contents
Editorial
Volume 5 number 3 April 2004
Treatment alerts
Risk factors for severe, life-threatening and fatal hepatotoxicity with nevirapine
Conference reports
11th Conference on Retroviruses and Opportunistic Infections (CROI)
Drug levels can persist for more than two weeks after stopping efavirenz
Race affects absorption and clearance of efavirenz
Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination
Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome
Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T
COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation
Studies of new pipeline drugs
Little benefit seen for treatment during acute infection
Summary of resistance studies at Retrovirus
Update on peripheral neuropathy in HIV-infection
Smoking marijuana provides analgesic effect on HIV neuropathy
Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure
Low-dose rHGH maintains reductions in abdominal fat for 60 weeks
HTB RSS
Current issues
March 2024
February 2024
January 2024
Back issues
Special report
Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all
12 February 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage